Pāriet uz galveno navigāciju Pāriet uz meklēšanu Pāriet uz galveno saturu

Adherence to the “Atrial fibrillation Better Care” (ABC) pathway in patients with atrial fibrillation and cancer: A report from the ESC-EHRA EURObservational Research Programme in atrial fibrillation (EORP-AF) General Long-Term Registry

  • Marco Vitolo
  • , Marco Proietti
  • , Vincenzo L. Malavasi
  • , Niccolo’ Bonini
  • , Giulio Francesco Romiti
  • , Jacopo F. Imberti
  • , Laurent Fauchier
  • , Francisco Marin
  • , Michael Nabauer
  • , Tatjana S. Potpara
  • , Gheorghe Andrei Dan
  • , Zbigniew Kalarus
  • , Aldo Pietro Maggioni
  • , Deirdre A. Lane
  • , Gregory Y.H. Lip
  • , Giuseppe Boriani
  • , L. Tavazzi
  • , Andrejs Ērglis
  • Institute of Cardiology and Regenerative Medicine
  • University of Modena and Reggio Emilia
  • University of Milan
  • University of Murcia
  • Ludwig Maximilian University of Munich
  • Clinical Center of Serbia
  • Carol Davila University of Medicine and Pharmacy
  • Medical University of Silesia in Katowice
  • Aalborg University
  • University of Birmingham
  • Paula Stradina Clinical University Hospital

Zinātniskās darbības rezultāts: Devums žurnālamZinātniskais raksts (žurnālā)koleģiāli recenzēts

31 Atsauces (Scopus)

Kopsavilkums

Background: Implementation of the Atrial fibrillation Better Care (ABC) pathway is recommended by guidelines on atrial fibrillation (AF), but the impact of adherence to ABC pathway in patients with cancer is unknown. Objectives: To investigate the adherence to ABC pathway and its impact on adverse outcomes in AF patients with cancer. Methods: Patients enrolled in the EORP-AF General Long-Term Registry were analyzed according to (i) No Cancer; and (ii) Prior or active cancer and stratified in relation to adherence to the ABC pathway. The composite Net Clinical Outcome (NCO) of all-cause death, major adverse cardiovascular events and major bleeding was the primary endpoint. Results: Among 6550 patients (median age 69 years, females 40.1%), 6005 (91.7%) had no cancer, while 545 (8.3%) had a diagnosis of active or prior cancer at baseline, with the proportions of full adherence to ABC pathway of 30.6% and 25.7%, respectively. Adherence to the ABC pathway was associated with a significantly lower occurrence of the primary outcome vs. non-adherence, both in ‘no cancer’ and ‘cancer’ patients [adjusted Hazard Ratio (aHR) 0.78, 95% confidence interval (CI): 0.66–0.92 and aHR 0.59, 95% CI 0.37–0.96, respectively]. Adherence to a higher number of ABC criteria was associated with a lower risk of the primary outcome, being lowest when 3 ABC criteria were fulfilled (no cancer: aHR 0.54, 95%CI: 0.36–0.81; with cancer: aHR 0.32, 95% CI 0.13–0.78). Conclusion: In AF patients with cancer enrolled in the EORP-AF General Long-Term Registry, adherence to ABC pathway was sub-optimal.

OriģinālvalodaAngļu
Lapas (no-līdz)54-62
Lapu skaits9
ŽurnālsEuropean Journal of Internal Medicine
Sējums105
DOIs
Publikācijas statussPublicēts - 1 nov. 2022

ANO IAM

Šis izpildes rezultāts palīdz sasniegt šādus ANO ilgtspējīgas attīstības mērķus (IAM)

  1. 3. IAM — Laba Veselība un Labbūtība
    3. IAM — Laba Veselība un Labbūtība

OECD Zinātnes nozare

  • 3. Medicīnas un veselības zinātnes

Nospiedums

Uzziniet vairāk par pētniecības tēmām “Adherence to the “Atrial fibrillation Better Care” (ABC) pathway in patients with atrial fibrillation and cancer: A report from the ESC-EHRA EURObservational Research Programme in atrial fibrillation (EORP-AF) General Long-Term Registry”. Kopā tie veido unikālu nospiedumu.

Citēt šo